Background Pediatric Inflammatory Bowel Disease (PIBD) is a chronic relapsing condition requiring repeated invasive assessments. Non-invasive biomarkers could reduce patient burden and support disease monitoring. Although salivary biomarkers represent a promising diagnostic tool, their role in PIBD remains poorly explored. Objective The aim of this study was to evaluate salivary lymphocytes in children with PIBD and assess their potential role as non-invasive biomarkers of disease activity. Materials and Methods In this prospective observational study, saliva samples from PIBD patients (<18 years) and healthy controls (including well-controlled celiac patients) were collected using E-saliva and Salivette® devices (Esamed, Italy) and analyzed by flow cytometry (DxFlex, Beckman Coulter, Italy). Total lymphocyte counts, T, B, NK lymphocytes, CD4+/CD8+ ratio, and HLA-DR expression on T lymphocytes were assessed. Clinical, biochemical, and endoscopic data were collected to investigate associations with disease phenotype, activity (PUCAI, PCDAI scores), and treatment response. Descriptive and comparative statistical analyses were conducted to assess between group differences and associations among variables. Statistical significance was defined as a p-value < 0.05. Results 67 PIBD patients (30 females; median age 15.1 years) and 58 controls (31 females; median age 11.9 years) provided 182 saliva samples. Salivary lymphocytes were detected in 22% of PIBD patients (16% of samples), whereas 97% of controls were negative. Most salivary lymphocytes were CD4+T cells, HLA-DR expression indicated an activated phenotype, independent of markers of systemic inflammation. Crohn’s disease accounted for 90% of positive samples (p<0.001). Associations with disease activity and inflammatory markers approached significance but were not statistically significant. Two treatment-naïve patients became negative after four months of anti-TNF therapy, suggesting potential responsiveness to biologic modulation. Conclusions This study is one of the first to provide evidence supporting the feasibility of studying salivary lymphocytes for PIBD diagnosis and monitoring. Activated CD4+ T cells may reflect mucosal immune activity and represent a novel non-invasive biomarker for disease monitoring and therapeutic response. Larger multicenter studies are warranted to validate these findings and further define the immunological landscape of the salivary compartment in PIBD.
Background Pediatric Inflammatory Bowel Disease (PIBD) is a chronic relapsing condition requiring repeated invasive assessments. Non-invasive biomarkers could reduce patient burden and support disease monitoring. Although salivary biomarkers represent a promising diagnostic tool, their role in PIBD remains poorly explored. Objective The aim of this study was to evaluate salivary lymphocytes in children with PIBD and assess their potential role as non-invasive biomarkers of disease activity. Materials and Methods In this prospective observational study, saliva samples from PIBD patients (<18 years) and healthy controls (including well-controlled celiac patients) were collected using E-saliva and Salivette® devices (Esamed, Italy) and analyzed by flow cytometry (DxFlex, Beckman Coulter, Italy). Total lymphocyte counts, T, B, NK lymphocytes, CD4+/CD8+ ratio, and HLA-DR expression on T lymphocytes were assessed. Clinical, biochemical, and endoscopic data were collected to investigate associations with disease phenotype, activity (PUCAI, PCDAI scores), and treatment response. Descriptive and comparative statistical analyses were conducted to assess between group differences and associations among variables. Statistical significance was defined as a p-value < 0.05. Results 67 PIBD patients (30 females; median age 15.1 years) and 58 controls (31 females; median age 11.9 years) provided 182 saliva samples. Salivary lymphocytes were detected in 22% of PIBD patients (16% of samples), whereas 97% of controls were negative. Most salivary lymphocytes were CD4+T cells, HLA-DR expression indicated an activated phenotype, independent of markers of systemic inflammation. Crohn’s disease accounted for 90% of positive samples (p<0.001). Associations with disease activity and inflammatory markers approached significance but were not statistically significant. Two treatment-naïve patients became negative after four months of anti-TNF therapy, suggesting potential responsiveness to biologic modulation. Conclusions This study is one of the first to provide evidence supporting the feasibility of studying salivary lymphocytes for PIBD diagnosis and monitoring. Activated CD4+ T cells may reflect mucosal immune activity and represent a novel non-invasive biomarker for disease monitoring and therapeutic response. Larger multicenter studies are warranted to validate these findings and further define the immunological landscape of the salivary compartment in PIBD.
Assessment of Salivary Lymphocytes as a Non-Invasive Biomarker in Pediatric Inflammatory Bowel Disease
PAIUSCO, GIADA
2024/2025
Abstract
Background Pediatric Inflammatory Bowel Disease (PIBD) is a chronic relapsing condition requiring repeated invasive assessments. Non-invasive biomarkers could reduce patient burden and support disease monitoring. Although salivary biomarkers represent a promising diagnostic tool, their role in PIBD remains poorly explored. Objective The aim of this study was to evaluate salivary lymphocytes in children with PIBD and assess their potential role as non-invasive biomarkers of disease activity. Materials and Methods In this prospective observational study, saliva samples from PIBD patients (<18 years) and healthy controls (including well-controlled celiac patients) were collected using E-saliva and Salivette® devices (Esamed, Italy) and analyzed by flow cytometry (DxFlex, Beckman Coulter, Italy). Total lymphocyte counts, T, B, NK lymphocytes, CD4+/CD8+ ratio, and HLA-DR expression on T lymphocytes were assessed. Clinical, biochemical, and endoscopic data were collected to investigate associations with disease phenotype, activity (PUCAI, PCDAI scores), and treatment response. Descriptive and comparative statistical analyses were conducted to assess between group differences and associations among variables. Statistical significance was defined as a p-value < 0.05. Results 67 PIBD patients (30 females; median age 15.1 years) and 58 controls (31 females; median age 11.9 years) provided 182 saliva samples. Salivary lymphocytes were detected in 22% of PIBD patients (16% of samples), whereas 97% of controls were negative. Most salivary lymphocytes were CD4+T cells, HLA-DR expression indicated an activated phenotype, independent of markers of systemic inflammation. Crohn’s disease accounted for 90% of positive samples (p<0.001). Associations with disease activity and inflammatory markers approached significance but were not statistically significant. Two treatment-naïve patients became negative after four months of anti-TNF therapy, suggesting potential responsiveness to biologic modulation. Conclusions This study is one of the first to provide evidence supporting the feasibility of studying salivary lymphocytes for PIBD diagnosis and monitoring. Activated CD4+ T cells may reflect mucosal immune activity and represent a novel non-invasive biomarker for disease monitoring and therapeutic response. Larger multicenter studies are warranted to validate these findings and further define the immunological landscape of the salivary compartment in PIBD.| File | Dimensione | Formato | |
|---|---|---|---|
|
Paiusco_Giada.pdf
Accesso riservato
Dimensione
2.17 MB
Formato
Adobe PDF
|
2.17 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/120635